- Home
- RLTY vs ABEO Comparison
RLTY vs ABEO Comparison
Compare RLTY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | ABEO |
|---|---|---|
| Founded | 2022 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 280.2M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RLTY | ABEO |
|---|---|---|
| Price | $15.02 | $4.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 53.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.71 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $12.90 | $3.93 |
| 52 Week High | $15.97 | $7.54 |
Technical Indicators
Market Signals| Indicator | RLTY | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 53.38 |
| Support Level | $14.71 | $4.53 |
| Resistance Level | $15.39 | $5.62 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 70.92 | 79.86 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.